Cullinan Therapeutics, Inc. (CGEM)
After hours:
| Previous Close | 23.50 |
| Open | 22.86 |
| Bid | 22.52 x 200 |
| Ask | 22.60 x 200 |
| Day's Range | 22.00 - 24.31 |
| 52 Week Range | 7.64 - 30.19 |
| Volume | |
| Avg. Volume | 769,344 |
| Market Cap | 1.299B |
| Beta (5Y Monthly) | -0.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.13 |
| Earnings Date | Aug 08, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 33.00 |
GlobeNewswireCullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion mutations treated with zipalertinib who had progressed after prior amivantamab treatmentCAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced positive initial data in patients receiving zipalertinib after pr
- GlobeNewswire
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
CAMBRIDGE, Mass., May 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Nadim Ahmed, Chief Executive Officer and Jeffrey Jones, MD, MBA, Chief Medical Officer, will participate in a fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA, being held virtually on May 28 and 29, 2024. The fireside chat is scheduled for Wednesday, M
- GlobeNewswire
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
One of the hallmarks of cancer is the ability to avoid detection by the immune system. Cancer cells get selected for escape mechanisms that can render them invisible to immune cells. The resulting immune evasion enables tumor growth and metastasis. There is a significant unmet need for novel therapies that can help overcome immune evasion mechanisms employed by tumors. CLN-619 is a potential first-in-class humanized lgG1 monoclonal antibody that binds to the stress induced ligands MICA and MICB,
